The VITATOPS (Vitamins to Prevent Stroke) trial: Rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke

Cerebrovascular Diseases

Volumn 13, Issue 2, 2002, Pages 120-126

  Hankey, Graeme J ^a   Vasikaran, S D ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Homocysteine; Multivitamins; Stroke; Transient ischaemic attack; VITATOPS Trial

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; MULTIVITAMIN; PYRIDOXINE;

AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

EID: 0036187533     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047761     Document Type: Article

References (47)

1. Mortality by cause for eight regions of the world. Global burden of disease study
2. Global mortality, disability and the contribution of risk factors. Global burden of disease study
3. Stroke: How large a public health problem and how can the neurologist help?
4. Treatment and secondary prevention of stroke: Evidence, costs, and effects on individuals and populations
5. Long-term risk of first recurrent stroke in the Perth community stroke study
6. Modeling of risk factors for ischemic stroke. The Willis lecture
7. Plasma homocysteine and coronary heart disease: Systematic review of published epidemiological studies
8. Homocysteine and vascular disease
9. Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence
10. Blood levels of homocysteine and increased risks of cardiovascular disease: Causal or casual?
11. Association between high homocyst(e)ine and ischaemic stroke due to large- and small-artery disease but not other etiological subtypes of ischaemic stroke
12. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia
13. Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells
14. Induction of monocyte tissue factor expression by homocysteine: A possible mechanism for thrombosis
15. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: A potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism
16. Hyperhomocysteinemia in chronic renal disease
17. An alternative view of homocysteine
18. Plasma homocysteine concentrations in the acute and convalescent periods of atherothrombotic stroke
19. Plasma homocysteine in the acute and convalescent phases after stroke
20. Serial measures of plasma homocyst(e)ine after acute myocardial infarction
21. Methylenetetrahydrofolate reductase gene and coronary artery disease
22. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not vascular disease: The results of a meta-analysis
23. The environment and disease: Association or causation
24. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials
25. Treatment of hyperhomocysteinaemia in renal transplant recipients
26. Treatment of mild hyperhomocysteinemia in vascular disease patients
27. 6 plus folate therapy in young patients with arteriosclerosis and hyperhomocysteinemia
28. 6 and folate nutritional status in men with hyperhomocysteinemia
29. Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia
30. Folic acid improves arterial endothelial function in adults with hyperhomocysteinemia
31. 5-Methyl-tetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia
32. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects
33. Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A randomized placebo-controlled trial
34. Influence of folic acid on postprandial endothelial dysfunction
35. Effect of folic acid and antioxi-dant vitamins on endothelial dysfunction in patients with coronary artery disease
36. What levels of plasma homocyst(e)ine should be treated? Effect of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 micromol/l
37. 6 on progression of subclinical atherosclerosis: A randomised, placebo-controlled trial
38. Vitamin Intervention for Stroke Prevention (VISP) trial: Rationale and design
39. VITAmins TO Prevent Stroke (VITATOPS): Major ongoing stroke trials
40. Psychometric properties of the Hospital Anxiety and Depression Scale with a population of members of a depression self-help group
41. 'Mini-Mental State': A practical method for grading the cognitive state of patients for the clinician
42. A randomised blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
43. Homocysteine in cerebral macroangiopathy and microangiopathy
44. MRI white matter hyperintensities. Three-year follow-up of the Austrian Stroke Prevention Study
45. Homocysteine: To screen and treat or to wait and see?
46. Homocyst(e)ine, diet, and cardiovascular diseases. A statement for healthcare professionals from the Nutrition Committee, American Heart Association